These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 10429739)
1. Review article: effects of the 5-HT3 receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle. Audolfsson G; Bayguinov O; Yamamoto T; Somogyi GT; Schraut WH; Sanders KM; Bauer AJ Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():39-47. PubMed ID: 10429739 [TBL] [Abstract][Full Text] [Related]
2. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. Prins NH; Akkermans LM; Lefebvre RA; Schuurkes JA Br J Pharmacol; 2001 Nov; 134(6):1351-9. PubMed ID: 11704657 [TBL] [Abstract][Full Text] [Related]
3. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function. Kawano K; Mori T; Fu L; Ito T; Niisato T; Yoshida S; Shiokawa S; Sato Y; Murakami H; Shishikura T Neurogastroenterol Motil; 2005 Apr; 17(2):290-301. PubMed ID: 15787949 [TBL] [Abstract][Full Text] [Related]
4. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Leclere PG; Prins NH; Schuurkes JA; Lefebvre RA Neurogastroenterol Motil; 2005 Jun; 17(3):366-75. PubMed ID: 15916624 [TBL] [Abstract][Full Text] [Related]
5. Inward currents in neurons from newborn guinea pig intestine: mediation by 5-hydroxytryptamine type 3 receptors. Zhai J; Gershon MD; Walsh JH; Wong HC; Kirchgessner AL J Pharmacol Exp Ther; 1999 Oct; 291(1):374-82. PubMed ID: 10490927 [TBL] [Abstract][Full Text] [Related]
6. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Humphrey PP; Bountra C; Clayton N; Kozlowski K Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of solifenacin on human isolated urinary bladder. Masunaga K; Yoshida M; Inadome A; Murakami S; Sugiyama Y; Satoji Y; Maeda Y; Ueda S Pharmacology; 2008; 82(1):43-52. PubMed ID: 18434763 [TBL] [Abstract][Full Text] [Related]
8. Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod. Mathison R; Shaffer E BMC Gastroenterol; 2006 Feb; 6():8. PubMed ID: 16504074 [TBL] [Abstract][Full Text] [Related]
9. Review article: evaluation of drugs in experimental gut distension models. Pappas TN; Mangel AW; Lawson C Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():54-6. PubMed ID: 10429741 [TBL] [Abstract][Full Text] [Related]
10. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Cellek S; John AK; Thangiah R; Dass NB; Bassil AK; Jarvie EM; Lalude O; Vivekanandan S; Sanger GJ Neurogastroenterol Motil; 2006 Sep; 18(9):853-61. PubMed ID: 16918765 [TBL] [Abstract][Full Text] [Related]
11. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693 [TBL] [Abstract][Full Text] [Related]
12. The prokinetic-like activity of ghrelin in rat isolated stomach is mediated via cholinergic and tachykininergic motor neurones. Bassil AK; Dass NB; Sanger GJ Eur J Pharmacol; 2006 Aug; 544(1-3):146-52. PubMed ID: 16859671 [TBL] [Abstract][Full Text] [Related]
13. Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia. Miranda A; Peles S; McLean PG; Sengupta JN Pain; 2006 Dec; 126(1-3):54-63. PubMed ID: 16844296 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Rahimi R; Nikfar S; Abdollahi M Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935 [TBL] [Abstract][Full Text] [Related]
15. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Houghton LA; Foster JM; Whorwell PJ Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats. Sugiyama Y; Yoshida M; Masunaga K; Satoji Y; Maeda Y; Nagata T; Inadome A; Ueda S Int J Urol; 2008 Jan; 15(1):76-81. PubMed ID: 18184179 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. James AN; Ryan JP; Parkman HP Am J Physiol Gastrointest Liver Physiol; 2003 Aug; 285(2):G291-7. PubMed ID: 12660140 [TBL] [Abstract][Full Text] [Related]
19. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Funatsu T; Takeuchi A; Hirata T; Keto Y; Akuzawa S; Sasamata M Eur J Pharmacol; 2007 Nov; 573(1-3):190-5. PubMed ID: 17658508 [TBL] [Abstract][Full Text] [Related]
20. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]